Citius Oncology Wins Nasdaq Extension to April 19, 2027 to Reclaim $1.00 Bid
CTOR sits 18% above its 52-week low of $0.491.
Summary
Nasdaq extended Citius Oncology's deadline to regain the $1.00 bid price to April 19, 2027. With the stock at $0.5795, the company must roughly double the share price and hold it for ten consecutive business days or face delisting.
Key Events · Legal and Risk Events · CTOR
-
Nasdaq Grants Bid-Price Extension
On October 19, 2026, Nasdaq granted Citius an extension through April 19, 2027 to evidence compliance with the $1.00 per share minimum bid requirement under Listing Rule 5550(a)(2).
-
Compliance Requires Ten-Day Run
The company regains compliance only if its closing bid is $1.00 or more for a minimum of ten consecutive business days before April 19, 2027; at today's $0.5795 the stock must roughly double.
-
Delisting Risk Still Live
If compliance is not regained by April 19, 2027, Nasdaq will issue a written delisting notice, which the company may appeal to a Nasdaq hearings panel; the filing states no assurance compliance can be achieved.
-
Stacks on Going-Concern Warning
The extension follows the August 14, 2026 10-Q, which previously disclosed a going concern warning, deepening losses and Nasdaq delisting risk, leaving a reverse split or dilutive raise as likely compliance paths.
Analysis · CTOR · Life Sciences
Citius gets roughly six more months on the Nasdaq Capital Market, but the clock is now explicit: the stock must close at $1.00 or higher for ten straight business days before April 19, 2027 or Nasdaq issues a delisting notice. At $0.5795 today, the shares need to roughly double just to reach the threshold, and the company says it is still evaluating options with no assurance it can comply. This lands on top of the going concern warning and deepening losses already disclosed in the August 10-Q, so the extension buys time rather than solving the problem — and the most likely compliance route for a cash-burning microcap is a reverse split or another dilutive raise.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1025 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.9M. The 52-week trading range was $0.49 to $1.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.